JAMA Oncol：特瑞普利单抗 vs达卡巴嗪？中国晚期肢端型黑色素瘤一线治疗的疗效与安全性评估

动脉网01-04

JAMA Oncology发表了一项在中国11个中心进行的多中心、开放标签的III期随机临床试验（MELATORCH研究），旨在比较PD-1抑制剂特瑞普利单抗与达卡巴嗪在晚期肢端型黑色素瘤一线治疗中的疗效与安全性。肢端黑色素瘤在中国占所有病例的50%，且预后较差，而西方国家主要以非肢端皮肤黑色素瘤为主。尽管免疫治疗已改变晚期黑色素瘤的治疗格局，但针对未经治疗的肢端黑色素瘤患者，PD-1抑制剂的疗效...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2600042608?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-04 13:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2600042608","market":"hk","top_or_hot":-1,"title":"JAMA Oncol：特瑞普利单抗 vs达卡巴嗪？中国晚期肢端型黑色素瘤一线治疗的疗效与安全性评估","media":"动脉网","content":"<div>\n<p>JAMA Oncology发表了一项在中国11个中心进行的多中心、开放标签的III期随机临床试验（MELATORCH研究），旨在比较PD-1抑制剂特瑞普利单抗与达卡巴嗪在晚期肢端型黑色素瘤一线治疗中的疗效与安全性。肢端黑色素瘤在中国占所有病例的50%，且预后较差，而西方国家主要以非肢端皮肤黑色素瘤为主。尽管免疫治疗已改变晚期黑色素瘤的治疗格局，但针对未经治疗的肢端黑色素瘤患者，PD-1抑制剂的疗效...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104133317a499b6fd&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JAMA Oncol：特瑞普利单抗 vs达卡巴嗪？中国晚期肢端型黑色素瘤一线治疗的疗效与安全性评估</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJAMA Oncol：特瑞普利单抗 vs达卡巴嗪？中国晚期肢端型黑色素瘤一线治疗的疗效与安全性评估\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-04 13:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104133317a499b6fd&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JAMA Oncology发表了一项在中国11个中心进行的多中心、开放标签的III期随机临床试验（MELATORCH研究），旨在比较PD-1抑制剂特瑞普利单抗与达卡巴嗪在晚期肢端型黑色素瘤一线治疗中的疗效与安全性。肢端黑色素瘤在中国占所有病例的50%，且预后较差，而西方国家主要以非肢端皮肤黑色素瘤为主。尽管免疫治疗已改变晚期黑色素瘤的治疗格局，但针对未经治疗的肢端黑色素瘤患者，PD-1抑制剂的疗效...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104133317a499b6fd&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104133317a499b6fd&s=b","article_id":"2600042608","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104133317a499b6fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2600042608","pubTimestamp":1767504300,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"JAMA Oncology发表了一项在中国11个中心进行的多中心、开放标签的III期随机临床试验（MELATORCH研究），旨在比较PD-1抑制剂特瑞普利单抗与达卡巴嗪在晚期肢端型黑色素瘤一线治疗中的疗效与安全性。肢端黑色素瘤在中国占所有病例的50%，且预后较差，而西方国家主要以非肢端皮肤黑色素瘤为主。尽管免疫治疗已改变晚期黑色素瘤的治疗格局，但针对未经治疗的肢端黑色素瘤患者，PD-1抑制剂的疗效与安全性缺乏高质量证据支持。在中国，对于无BRAF突变的晚期黑色素瘤，化疗（尤其是达卡巴嗪）一直是唯一的一线标准治疗方案，但其疗效有限。MELATORCH研究为这一临床难题提供了关键答案。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","01877":"君实生物","BK1161":"生物科技","BK1515":"抗疫概念"},"translate_title":"JAMA Oncol: toripalimab vs dacarbazine? Efficacy and safety assessment of first-line treatment of advanced acromelanoma in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":0.9},"content_text":"JAMA Oncology发表了一项在中国11个中心进行的多中心、开放标签的III期随机临床试验（MELATORCH研究），旨在比较PD-1抑制剂特瑞普利单抗与达卡巴嗪在晚期肢端型黑色素瘤一线治疗中的疗效与安全性。肢端黑色素瘤在中国占所有病例的50%，且预后较差，而西方国家主要以非肢端皮肤黑色素瘤为主。尽管免疫治疗已改变晚期黑色素瘤的治疗格局，但针对未经治疗的肢端黑色素瘤患者，PD-1抑制剂的疗效与安全性缺乏高质量证据支持。在中国，对于无BRAF突变的晚期黑色素瘤，化疗（尤其是达卡巴嗪）一直是唯一的一线标准治疗方案，但其疗效有限。MELATORCH研究为这一临床难题提供了关键答案。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600042608","isCrawlerRequest":true}